Related Experiment Video

Updated: Jun 12, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

Motor neuron-immune interactions: the vicious circle of ALS

Ana G Barbeito1, Pinar Mesci, Séverine Boillée

  • 1Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière, Institut National de la Santé et de la Recherche Médicale (INSERM), Unité Mixte de Recherche S-975, 75013 Paris, France.

Journal of Neural Transmission (Vienna, Austria : 1996)
|June 17, 2010
PubMed

Insights

Microglia and the immune system play a role in amyotrophic lateral sclerosis (ALS) progression. Understanding these neuro-immune interactions could reveal new therapeutic targets for motor neuron disease.

Area of Science:

  • Neuroimmunology
  • Neurodegenerative Diseases

Background:

  • Microglial cells, the CNS's resident macrophages, are activated by nervous system lesions.
  • Their role in neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), is increasingly recognized.
  • The innate and adaptive immune responses are implicated in ALS pathogenesis.

Purpose of the Study:

  • To investigate the mechanisms by which microglial cells influence motor neuron death in ALS.
  • To explore the role of immune system interactions in ALS physiopathology.

Main Methods:

  • The study focuses on analyzing microglial activation and immune responses in mouse models of ALS.
  • Investigating the production of neurotoxic and neurotrophic factors by activated microglia.

Main Results:

  • Microglial activation intensifies as ALS progresses.
  • Altered production of toxic and neurotrophic factors by activated microglia is observed.
  • Both innate and adaptive immune systems influence the disease process.

Conclusions:

  • Motor neuron degeneration in ALS involves complex neuro-immune interactions.
  • Further exploration of these interactions may identify novel therapeutic strategies to slow motor neuron loss.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-409:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...